Amylin, Lilly: Two-year study shows Byetta sustains blood glucose control

By Elaine Rigoli

Tampa, Fla., June 12 - Amylin Pharmaceuticals, Inc. and Eli Lilly and Co. announced two-year study results showing that Byetta (exenatide) injection sustained improvements in blood sugar control and reduced body weight in people with type 2 diabetes who previously did not achieve adequate control of their blood sugar on common oral medications.

After two years of treatment, patients sustained an average hemoglobin A1C reduction of 1.1% from baseline, according to a news release.

This A1C reduction compares to an A1C reduction of 1.1% at the end of the initial 30-week clinical trial, demonstrating sustained efficacy over the two-year period.

A1C measures a person's average glucose level over a three-month period and is often used by doctors to assess blood glucose management.

Also, average weight loss improved to 10 pounds from the average of five pounds seen after 30 weeks. Fasting blood glucose was reduced 25 mg/dL.

Byetta was approved in April 2005 as an adjunctive therapy for patients who are not achieving blood sugar control on metformin and/or a sulfonylurea.

Amylin is a biopharmaceutical company based in San Diego.

Eli Lilly, is a global pharmaceutical company headquartered in Indianapolis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.